Bill > HR2405

This bill, the Streamlining Research on Controlled Substances Act of 2021, aims to improve the process for conducting scientific research on Schedule I controlled substances. Key provisions include: 1) Allowing researchers already registered to work with Schedule I or II substances to continue research on newly-scheduled substances without a new registration, provided they submit an application within 30 days. 2) Enabling registered Schedule I researchers to conduct research with other Schedule I substances without a new registration, as long as the research protocol is deemed meritorious by the Secretary of Health and Human Services. 3) Clarifying that certain activities, like processing substances to create extracts or develop dosage forms, can be considered coincident to approved research and do not require a separate manufacturing registration. 4) Requiring the Attorney General and Secretary of Health and Human Services to review the research registration process, evaluate impacts on diversion risks, and identify opportunities to reduce burdens for researchers.

Business and Industry, Health and Social Services, Military Affairs and Security

https://www.congress.gov/bill/117th-congress/house-bill/2405/all-info